With Ciloa approach, knowledge of the gene sequence is the only requirement for producing antigen-bearing exosomes allowing efficient protective vaccination.
Exosomes are known to activate immune responses through various mechanisms, including transfering antigens to dendritic cells, presentating antigens to T lymphocytes, and activating natural killer cells.
In addition, several functional co-stimulatory molecules naturally present on exosomes are able to enhance immune responses. Thus, exosomes presenting antigens trigger efficient protection without any added adjuvants.
No pathogens are necessary to develop vaccines against tumor cells, viruses, bacteria or parasites using membrane proteins (GPCRs, viral envelope proteins …) sorted with their native conformation on exosomes.
The combination of both, a perfect antigen and a potent natural adjuvant effect leads to the perfect candidate vaccine.
As cell-free nanovesicules that do not require the use of a viral machinery for assembly, exosome-based vaccines offer a high bio-safety profile. The scale-up of exosome based vaccines for clinical assays, has been already reported.